Rare-disease pipelines advance at AskBio and BridgeBio; telehealth Hims misses

AskBio dosed the first patient in a phase 1/2 gene-therapy trial for late-onset Pompe disease, while BridgeBio filed an FDA new-drug application for encaleret in autosomal dominant hypocalcemia type 1. Meanwhile, as telehealth competition in compounded GLP-1s intensified, Hims & Hers reported quarterly revenue below consensus on May 12 and shares weakened.